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Available online 16 June 2016Long-term efﬁcacy and safety of elosulfase alfa enzyme replacement therapy were evaluated in Morquio A
patients over 96 weeks (reaching 120 weeks in total from pre-treatment baseline) in an open-label, multi-
center, phase III extension study. During this extension of a 24-week placebo-controlled phase III study, all
patients initially received 2.0 mg/kg elosulfase alfa either weekly or every other week, prior to establish-
ment of 2.0 mg/kg/week as the recommended dose, at which point all patients received weekly treatment.
Efﬁcacy measures were compared to baseline of the initial 24-week study, enabling analyses of changes
over 120 weeks. In addition to performing analyses for the entire intent-to-treat (ITT) population (N =
173), analyses were also performed for a modiﬁed per-protocol (MPP) population (N = 124), which ex-
cluded patients who had orthopedic surgery during the extension study or were non-compliant with the
study protocol (as determined by ≥20% missed infusions). Six-minute walk test (6MWT) was the primary
efﬁcacy measure; three-minute stair climb test (3MSCT) and normalized urine keratan sulfate (uKS) were
secondary efﬁcacy measures. Mean (SE) change from baseline to Week 120 in 6MWT distance was 32.0
(11.3) m and 39.9 (10.1) m for patients receiving elosulfase alfa at 2.0 mg/kg/week throughout the
study (N = 56) and 15.1 (7.1) m and 31.7 (6.8) m in all patients combined, regardless of dosing regimen,
for the ITT and MPP populations, respectively. Further analyses revealed that durability of 6MWT improve-
ments was not impacted by baseline 6MWT distance, use of a walking aid, or age. Mean (SE) change at
Week 120 in the 3MSCT was 5.5 (1.9) and 6.7 (2.0) stairs/min for patients receiving elosulfase alfa at
2.0 mg/kg/week throughout the study and 4.3 (1.2) and 6.8 (1.3) stairs/min in all patients combined,
regardless of dosing regimen, for the ITT and MPP populations, respectively Across all patients, mean
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132 C.J. Hendriksz et al. / Molecular Genetics and Metabolism 119 (2016) 131–143populations, respectively. In the absence of a placebo group, signiﬁcance of the sustained improvements
could not be evaluated directly. However, to provide context for interpretation of results, comparisons
were performed with untreated patients from a Morquio A natural history study. In contrast to the results
of the extension study, the untreated patients experienced constant uKS levels and a gradual decline in en-
durance test results over a similar period of time. Differences from the untreated natural history study pa-
tients were signiﬁcant for 6MWT, 3MSCT, and uKS outcomes for the cohort of patients receiving optimal
dosing throughout the study and for all cohorts pooled together, for both ITT and MPP populations
(P b 0.05). Safety ﬁndings were consistent with those of the initial 24-week study, with no new safety sig-
nals identiﬁed.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Morquio A syndrome (mucopolysaccharidosis IVA) is a rare autoso-
mal recessive disorder caused bymutations in the lysosomal enzymeN-
acetylgalactosamine-6-sulfatase (GALNS, EC 3.1.6.4). Reduced GALNS
enzyme activity results in progressive accumulation of chondroitin-6-
sulfate and keratan sulfate (KS) in tissues and organs, leading to dys-
functions in multiple organ systems [1–3]. Due to the rarity of Morquio
A syndrome and variations in reporting methods used, accurate
prevalence and incidence estimates have not yet been established,
with reported birth prevalence ranging widely from 1 in 71,000 to
1,179,000 [4].
Characteristic features of Morquio A include skeletal and joint ab-
normalities, short stature, cardiorespiratory compromise, nerve entrap-
ment syndromes, impaired vision, hearing loss, and hepatomegaly
[1–3]. There is a wide heterogeneity among patients in genotype, clini-
cal presentation, and progression rate. However, regardless of an
individual's presentation of the disease, over time, the progressive na-
ture of symptoms ultimately results in deteriorating mobility and en-
durance, limitations in performing the activities of daily life, and early
mortality [5,6].
Enzyme replacement therapy (ERT) with recombinant human
GALNS (elosulfase alfa, Vimizim®, BioMarin Pharmaceutical Inc., Nova-
to, CA) has recently been approved as a treatment option for Morquio A
[7]. The pivotal 24-week, randomized, placebo-controlled, phase III
study showed signiﬁcant improvements with weekly elosulfase alfa in-
fusions (2.0 mg/kg) on the primary efﬁcacy measure, i.e. distance
walked in the 6MWT [8]. After 24 weeks of treatment, 6MWT distance
increased by 22.5 m versus placebo (P = 0.017). No effect was seen
with elosulfase alfa administered every other week. In addition, the
study demonstrated non-statistical increases in the 3MSCT and pulmo-
nary function tests versus placebo [8,9]. Normalized urine KS (uKS) was
reduced at 24 weeks with both treatment regimens. Long-term safety
and efﬁcacy data from an extension of this pivotal study are reported
in this manuscript.2. Methods
2.1. Study design
The study (MOR-005, #NCT01415427) was a multi-national, multi-
center, open-label extension of a randomized, double-blind, placebo-
controlled, 24-week, phase III study (MOR-004, #NTC01275066) of
176 Morquio A patients [8,9]. The inclusion and exclusion criteria and
study design have been published previously [8,9] and included re-
quirements that patients were ≥5 years of age, had a baseline average
6MWT distance ≥30 and ≤325 m at baseline, and did not have major
surgery within the 3 months prior to MOR-004 entry. For consistency,
both MOR-004 and MOR-005 protocols mandated uniform walking
aid use during endurance tests from baseline through last visit. All
patients completing MOR-004 were eligible for enrollment inMOR-005. Before entering MOR-005, all participants, and/or their
legally authorized representative (as required), provided written
informed consent.
In part 1 of MOR-005, patients initially randomized to elosulfase alfa
remained on their assigned dosing regimen of 2.0 mg/kg/week (QW-
QW cohort) or 2.0 mg/kg/every other week (QOW-QOW cohort);
placebo-treated patients were re-randomized (1:1) to one of the two
dosing regimens (Fig. 1). Unlike randomization at initiation of MOR-
004, re-randomization was not stratiﬁed by age or baseline 6MWT.
After review of ﬁnal efﬁcacy and safety results fromMOR-004 by an in-
dependent data monitoring committee, the recommended dose was
established as 2.0 mg/kg/week. As pre-speciﬁed in the protocol, all pa-
tients were switched to the recommended dose for part 2 of study. Spe-
ciﬁc studyweek of transition depended on study enrollment timing and
ranged from MOR-004/005 Week 36 to 96.
Although surgeries were not allowed during MOR-004, due to the
long-term nature of the extension study, they could not reasonably be
prohibited during MOR-005. However, endurance test results can be
impacted by the occurrence of orthopedic surgery and the subsequent
recovery period. Therefore, the per-protocol population for analysis ex-
cluded data on or after orthopedic surgery, as well as 24 week intervals
of datawhere ≥3 infusionsweremissed and all data subsequent to such
intervals. However, at a meeting on February 9, 2015 in Orlando, FL,
USA, study investigators determined that the pre-speciﬁed per-
protocol population was unnecessarily restricted and excluded too
many patients (95 patients excluded; 51 patients due to missing ≥3 in-
fusions) and established the modiﬁed per-protocol (MPP) population.
The MPP population excluded patients who underwent orthopedic sur-
gery during the study (N = 38) and/or exhibited recurrent non-
compliance with the study protocol. Missed infusions were used as an
indicator of compliance; patients missing ≥20% of their scheduled
elosulfase alfa infusions during MOR-005 were identiﬁed as non-
compliant (N = 14). In total, 49 patients were excluded, thereby
allowing inclusion of an additional 46 patients as compared to the
per-protocol population. To reveal the impact of orthopedic surgeries
and lack of compliance on endurance, MPP population results are pre-
sented alongside results from the entire intent-to-treat (ITT) population
(all patients who were previously included in the 24-week phase III
study and received at least one dose of elosulfase alfa).2.2. Efﬁcacy evaluation
The primary efﬁcacy variable of this extension study was dis-
tance walked in a 6MWT, which provides a measure for endurance.
The 3MSCT, also a measure of endurance, and normalized uKS were
secondary efﬁcacy variables. The uKS measurements were nor-
malized by dividing by urine creatinine levels, resulting in μg/mg
creatinine units.
In part 1 of MOR-005, the 6MWT and the 3MSCT were performed at
Week 12 andWeek 24, and at 24-week intervals thereafter. Normalized
uKS was assessed every 12 weeks. In part 2 of MOR-005, the 6MWT
Fig. 1. Study design.
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was assessed every 24 weeks. Endurance tests were performed in
duplicate (on separate days) and the average of the two measure-
ments was used as the score for that week. Patients who were phys-
ically unable to perform the endurance tests were scored as zero m
or stairs/min.
As continuing invasive weekly infusions in the absence of treatment
for the duration of this long-term extension study for this rare disorder
was considered unethical, a placebo group was not included. In the ab-
sence of a placebo group, a direct evaluation of treatment efﬁcacy could
not be made. However, to provide context for interpretation of results,
comparisons were performed with an untreated population from the
Morquio A Clinical Assessment Program (MorCAP) natural history
study (MOR-001, #NCT00787995). The study design of MorCAP has
been published previously [2,10]. Brieﬂy, MorCAP was a multi-
national, multi-center, cross-sectional study, later amended to be longi-
tudinal. Visits were conducted annually with each visit including collec-
tion ofmedical history, clinical assessments, and uKSmeasurement. The
subset of MorCAP patients meeting the following criteria: ≥5 years of
age and average 6MWT distance ≥30 and ≤325 m at baseline, for
whom longitudinal data (Year 1 and/or Year 2 follow-up) were avail-
able, were used to establish an untreated subpopulation (MorCAP
1) comparable to the MOR-005 ITT population. MorCAP 1 was further
restricted to exclude patients who underwent orthopedic surgery with-
in the 3 months prior to the time at which their baseline data were
collected or during the subsequent 2 year period to establish an un-
treated subpopulation (MorCAP 2) comparable to the MOR-005 MPP
population.2.3. Safety evaluation
Safety in MOR-005 was assessed by examining incidence, severity,
and relationship of elosulfase alfa to treatment-emergent adverse
events (AEs). Vital signs were measured just before, during, and imme-
diately after the infusion and at least 60min post-infusion. AEs and con-
comitant medications were recorded throughout the study and
reviewed every 4 months by an independent data monitoring commit-
tee. The following safety parameters were assessed every 12 weeksduring part 1 and then at 24-week intervals during part 2 of MOR-
005: infusion-associated reactions (IARs), standard clinical laboratory
results, physical examination, immunogenicity, and pregnancy testing
(as appropriate). IARs were deﬁned as any AE (regardless of drug rela-
tionship) occurring after infusion onset and within 1 day post infusion.
Routine immunogenicity testing included assays for anti-elosulfase alfa
total antibody (TAb), neutralizing antibody (NAb, a subset of TAb that
inhibit receptor binding), anti-elosulfase alfa immunoglobulin E (IgE),
and total IgE (baseline only). Immunogenicity tests were performed
using validated immunogenicity assays on blood samples as described
previously [11]. Samples were collected prior to study drug infusion at
baseline and at Weeks 2, 4, 8, 12, 16, 20, and 24 during MOR-004,
every 12 weeks in MOR-005 part 1, and every 24 weeks in MOR-005
part 2. TAb titers were determined by a bridging electro-
chemiluminescence assay that measures multiple anti-drug antibody
isotypes in a single assay. TAb-positive samples were conﬁrmed for
speciﬁcity against elosulfase alfa and serially diluted to obtain a titer. A
qualitative NAb assay was used to determine whether patient TAb
could neutralize binding of biotin-labeled elosulfase alfa to CI-M6PR
immobilized on an ELISA plate. When TAb was negative, NAb was not
assessed. Anti–elosulfase alfa IgE was detected by a sandwich radioim-
munoassay. Elosulfase alfa speciﬁcity was conﬁrmed for samples that
screened positive for anti-drug IgE and resultswere reported as positive
or negative. Subjects with a severe IAR or IAR requiring infusion cessa-
tion had an additional blood sample taken to assess total IgE, drug spe-
ciﬁc IgE levels, complement, and tryptase. Potential hypersensitivity AEs
were identiﬁed by utilizing the broadAnaphylactic Reaction algorithmic
Standardized Medical Dictionary of Regulatory Activities (MedDRA)
query (SMQ) (MedDRA, version 15.0, http://www.meddra.org/) and
the broad Angioedema SMQ.2.4. Statistical methods
The analyzed data were collected during both the initial 24-week
study and 96 weeks of the extension study, representing a total of
120 weeks. Descriptive statistics of efﬁcacy endpoints are provided for
both the ITT and MPP populations. A repeated measures ANCOVA
model including treatment, time point, treatment and time point
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line 6MWT distance stratiﬁcation (≤200 m and N200 m), and baseline
measurement (for 3MSCT and uKS) as factors was used for the compar-
ison of least squares mean (LS mean) changes from baseline at Year 1
and Year 2 between MOR-005 and MorCAP populations. Of the four
treatment cohorts, only the QW-QW cohort was directly compared to
MorCAP due to complications with assessment timing alignment
(PBO-QW, PBO-QOW) and/or variable dosing (PBO-QOW, QOW-
QOW) for the remaining cohorts. To reduce the impact of these compli-
cations, while still evaluating all available data, a general evaluation of
long-term (96 to 120week) elosulfase alfa treatment, regardless of dos-
ing regimen,was performed by comparingMorCAP 1 and 2with pooled
data from the combined cohorts for both the ITT and MPP populations,
respectively.
The safety analysis included all patients that received any dose of
study drug and had any post-treatment safety information. The inci-
dence rates for AEs were summarized by System Organ Class, Preferred
Term, relationship to study drug, and severity for each treatment group.
3. Results
3.1. Patient characteristics
Of the 176 patients enrolled in MOR-004, 175 completed MOR-004
(one patient withdrew after a single infusion) and 173 continued into
MOR-005 (two patients declined to provide informed consent for
MOR-005). One patient in the elosulfase alfaweekly dosing groupwith-
drew consent after completing week 0 of part 1. During part 2 of MOR-
005, 16 patients discontinued study drug with the majority of the dis-
continuations being due to early transition to commercial drug and ap-
proximately half occurring after 72 weeks. Two patients enrolled inTable 1














Mean ± SD 14.4 ± 10.2 16.7 ± 13.7 13.5 ± 8.5 15.3 ± 10.8 12
Median 11.7 11.1 11.9 12.0 10
Min, Max 5.0, 57.4 5.0, 57.4 5.0, 33.2 5.0, 49.1 5.
Gender, N (%)
Female 87 (50.3) 14 (48.3) 18 (62.1) 25 (42.4) 30
Male 86 (49.7) 15 (51.7) 11 (37.9) 34 (57.6) 26
Ethnicity, N (%)
White 113 (65.3) 25 (86.2) 18 (62.1) 35 (59.3) 35
Non-white 60 (34.7) 4 (13.8) 11 (37.9) 24 (40.7) 21
6MWT, m
Mean ± SD 209.5 ± 74.0 219.7 ± 74.2 207.2 ± 64.9 205.7 ± 81.2 20
Median 220.4 239.5 217.2 218.0 21
Min, Max 36.2, 321.5 36.2, 309.9 93.0, 312.2 47.1, 319.6 56
3MSCTa, stairs/min
Mean ± SD 29.1 ± 15.4 33.1 ± 15.6 26.9 ± 12.1 27.1 ± 15.8 30
Median 29.2 33.0 29.0 25.5 30
Min, Max 0.0, 71.9 0.0, 59.0 0.0, 50.0 0.0, 66.8 0.
uKSb,c, μg/mg
Mean ± SD 27.2 ± 17.2 22.7 ± 15.3 28.5 ± 14.9 28.6 ± 21.2 27
Median 26.6 25.0 30.3 27.4 25
Min, Max 2.1, 117.3 3.1, 50.5 2.5, 52.8 2.4, 117.3 2.
Table includes patients who entered MOR-005 using baseline values from MOR-004.
PBO-QOW: Placebo-elosulfase alfa 2.0 mg/kg/qow; PBO-QW: Placebo-elosulfase alfa 2.0 mg/kg
QOW-QOW: elosulfase alfa 2.0 mg/kg/qow-elosulfase alfa 2.0 mg/kg/qow; QW-QW: elosulfa
6MWT: 6-minute walk test; SD: standard deviation.
a N = 88 in MorCAP 1 and N= 74 in MorCAP 2.
b N = 28 in the PBO-QOW cohort, N= 172 in the total ITT group and N= 123 in the MPP
c uKS is calculated as urine keratan sulfate divided by urine creatinine.MOR-005 have not completed the study as they are waiting for an infu-
sion center to open nearer their place of residence.
Of the 353 patients in MorCAP, longitudinal data were available for
184. Of those subjects, 87 did not meet MOR-004/005 inclusion criteria
(28 were b5 years of age, 27 walked b30 m at baseline, and 32 walked
N325 m at baseline) and were excluded. Therefore, 97 untreated pa-
tients were used for comparison with the MOR-005 ITT population.
For comparison with the MOR-005 MPP population, 18 additional
MorCAP patients who had orthopedic surgery between 3 months prior
to baseline measurement collection and 2 years of follow-up were ex-
cluded. The incidence of surgeries was similar between MOR-004/005
(38/173, 22%) and MorCAP (18/97, 19%) patients.
Due to the observational nature of the natural history study, the
exact time of follow-up visits varied. Visit windows were 270 through
609 days for the Year 1 assessment and 610 through 944 days for the
Year 2 assessment. Mean (SD) actual visit times were 446 (74) and
749 (79) days, or approximately 64 and 107weeks, for Year 1 and 2, re-
spectively. These times were compared with MOR-004/005 72 and
120 week time points.
Table 1 shows demographics and characteristics for patients en-
rolled in MOR-005 as well as the corresponding subpopulations of
Morquio A patients from theMorCAP natural history study. Baseline de-
mographics and characteristics were relatively similar. Because the
number of MorCAP patients was substantially reduced at each time
point, baseline characteristics for the patients providing data at each
follow-up visit were examined. Despite the smaller samples sizes, base-
line characteristics remained similar (Appendix A).
Due to the transition to weekly dosing occurring at a speciﬁc date
when the recommended dose was established versus at a pre-
speciﬁed study visit, patients receiving QOW dosing were switched to








QW-QW N=43 MorCAP 2
N=79
.8 ± 8.0 16.3 ± 12.2 15.4 ± 10.3 13.5 ± 8.6 17.8 ± 13.0
.6 11.0 12.2 11.1 12.0
0, 41.9 5.0, 65.0 5.0, 49.1 5.0, 41.9 5.0, 65.0
(53.6) 56 (57.7) 58 (46.8) 22 (51.2) 48 (60.8)
(46.4) 41 (42.3) 66 (53.2) 21 (48.8) 31 (39.2)
(62.5) 86 (88.7) 84 (67.7) 28 (65.1) 72 (91.1)
(37.5) 11 (11.3) 40 (32.3) 15 (34.9) 7 (8.9)
9.4 ± 71.8 207.8 ± 84.3 201.6 ± 74.9 208.8 ± 73.2 210.4 ± 83.4
8.7 220.5 210.6 226.9 221.5
.3, 321.5 30.0, 325.0 36.2, 319.6 56.3, 309.0 30.0, 325.0
.1 ± 16.2 31.3 ± 17.5 28.7 ± 14.9 31.3 ± 16.2 32.2 ± 17.8
.7 29.3 29.6 31.3 30.6
0, 71.9 0.0, 85.6 0.0, 71.9 0.0, 71.9 0.0, 85.6
.2 ± 14.2 33.5 ± 25.6 25.5 ± 17.6 24.9 ± 13.1 32.2 ± 27.4
.0 30.7 23.4 23.4 27.6
1, 59.0 2.3, 168.1 2.1, 117.3 2.1, 52.8 2.3, 168.1
/week;
se alfa 2.0 mg/kg/week -elosulfase alfa 2.0 mg/kg/week; 3MSCT: 3-min stair climb test;
group for urine keratin sulfate (uKS).
Fig. 2.Mean (SE) change from baseline in 6MWT distance over 120 weeks for treatment cohorts individually (A, B) and pooled (C) for ITT andMPP populations. Not all patients reported
results for all time points (including MOR-005 Week 0); the number of patients with data available are shown below each time point.
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tients). Additionally, Week 48 endurance assessments were performed
only for subjects who reached Week 48 while in part 1 of the study as
therewas noWeek 48 assessment in part 2. This led to a greatly reduced
sample size at Week 48; therefore, this visit has been omitted from the
endurance analyses.
3.2. Primary efﬁcacy variable: 6MWT
In the ITT population, for patients treated for 120weekswith the op-
timal dosing regimen (QW-QW), the mean (SE) change in 6MWT dis-
tance from pre-treatment baseline was 37.2 (7.9) m at 24 weeks, 42.2
(7.1) m at 36 weeks, 30.7 (10.2) m at 72 weeks, and 32.0 (11.3) m at
120 weeks (Fig. 2A). ITT population results from the remaining treat-
ment cohorts did not indicate consistent improvements similar to
those seen in the QW-QW cohort (Fig. 2A). Notably, randomization of
the placebo (PBO) group to QW and QOW treatment was not stratiﬁed
by age or baseline endurance and resulted in unbalanced groups.
Evaluating the MPP population, which excluded non-compliant pa-
tients and those who underwent orthopedic surgery, reduced the over-
all variability of outcomes (Fig. 2B). Mean (SE) changes from baseline
for the QW-QW cohort were slightly higher: 41.5 (9.1), 44.4 (8.3),
37.5 (11.0), and 39.9 (10.1)m at 24, 36, 72, and 120weeks, respectively.
Outcomes for the PBO-QOW and PBO-QW groups were also more con-
sistent. Although the mean for the PBO-QOW group had increased
more than the PBO-QW group in the absence of treatment, both PBO-Fig. 3. LS mean 6MWT changes from baseline (m) over approximately 2 years in MOR-004
subpopulations from the MorCAP natural history study, MorCAP 1 and 2, respectively. The nu
are based on repeated measures ANCOVAmodel including treatment, time point, treatment anQW and PBO-QOW groups showed similar rates of improvement fol-
lowing initiation of treatment. Unfortunately, the staggered transition
of QOW-QOW patients to QW treatment precludes meaningful analysis
of QOW dosing efﬁcacy. However, an analysis of all cohorts pooled was
performed to evaluate the effect of long-term (96 to 120 weeks)
elosulfase alfa treatment, regardless of dosing regimen (Fig. 2C). Mean
(SE) change from baseline in 6MWT distance was 22.0 (3.9), 27.4
(4.3), 26.1 (6.2), and 15.1 (7.1) m and 27.3 (4.7), 33.2 (5.2), 39.6 (6.2),
and 31.7 (6.8) m at 24, 36, 72, and 120 weeks for the pooled cohort
ITT and MPP populations, respectively.
Assuming similar timingof approximately 1 and 2 years follow-up in
MorCAP and MOR-004/005, model-based ANCOVA analysis demon-
strates a signiﬁcant difference in change frombaseline for treated versus
untreated patients, for both the QW-QW cohort and the pooled study
population (ITT and MPP) (Fig. 3, Table 2).
Sub analyses of the 6MWTdatawere performed on theMPP popula-
tion of the QW-QW cohort to facilitate interpretation of the data in the
absence of potentially confounding factors (orthopedic surgeries and
extensive missed treatments/sub-optimal dosing) (Appendix B). Al-
though patients who used a walking aid (crutches, walker/walking
frame, or cane/walking stick) during the 6MWT began the extension
study with higher mean improvements in 6MWT distances than those
who did not, both groups maintained their initial improvements
throughout the study (Appendix Fig. B1). Similarly, patients who had
substantially limited baseline endurance (≤200 m 6MWT results)
began the extension study with higher mean improvements in 6MWT/005 QW-QW and pooled ITT and MPP populations and the corresponding untreated
mber of patients with data available are shown below each time point. LS mean changes
d time point interaction, age group, and baseline 6MWT category.
Table 2
LS mean change from baseline results for 6MWT, 3MSCT, and uKS and comparison with data from the corresponding untreated patients from the MorCAP natural history study.
Year 1a Year 2b
MorCAP MOR-004/005 QW-QW MOR-004/005 Pooled MorCAP MOR-004/005 QW-QW MOR-004/005 Pooled
ITT Population/MorCAP 1
6MWT (m)
N 80 54 166 40 51 154
LS mean change from baselinec (SE)d -8.4 (8.91) 31.8 (10.86) 25.5 (6.17) -16.4 (12.50) 32.1 (11.75) 16.8 (6.72)
P-valuee for difference from MorCAP 0.0046 0.0019 0.0050 0.0198
3MSCT (stairs/min)
N 80 54 164 40 51 154
LS mean change from baselinec (SE)d -0.7 (1.46) 5.0 (1.71) 5.1 (0.98) -1.1 (2.27) 5.3 (2.10) 4.3 (1.20)
P-valuee for difference from MorCAP 0.0129 0.0013 0.0407 0.0347
uKS (%)
N 72 51 160 23 47 142
LS mean change from baselinec (SE)d 32.7 (7.64) -57.6 (9.06) -56.8 (5.16) 5.6 (6.98) -63.8 (6.60) -60.9 (3.77)
P-valuee for difference from MorCAP b0.0001 b0.0001 b0.0001 b0.0001
MPP Population/MorCAP 2
6MWT (m)
N 67 43 123 27 41 117
LS mean change from baselinec (SE)d -6.7 (8.78) 38.5 (11.02) 38.4 (6.47) -21.9 (12.30) 39.0 (11.32) 32.9 (6.66)
P-valuee for difference from MorCAP 0.0016 b0.0001 0.0003 0.0001
3MSCT (stairs/min)
N 67 43 123 27 41 117
LS mean change from baselinec (SE)d 0.5 (1.51) 5.5 (1.85) 6.9 (1.08) -1.2 (2.39) 6.2 (2.24) 6.9 (1.32)
P-valuee for difference from MorCAP 0.0375 0.0007 0.0236 0.0033
uKS (%)
N 59 41 118 13 38 108
LS mean change from baselinec (SE)d 29.6 (9.30) -57.5 (11.16) -56.4 (6.59) 6.2 (8.46) -63.8 (7.47) -62.8 (4.41)
P-valuee for difference from MorCAP b0.0001 b0.0001 b0.0001 b0.0001
LS: least square; SE: standard error.
a Year 1 represents data collected from the MOR-004/005 Week 72 assessment and the MorCAP Year 1 follow-up window.
b Year 2 represents data collected from the MOR-004/005 Week 120 assessment and the MorCAP Year 2 follow-up.
c Baseline LS means are based on ANCOVA of baseline measurement with model terms treatment age group, and 6MWT distance category.
d LS mean changes based on repeated measures ANCOVA model including treatment, time point, treatment and time point interaction, age group, and baseline 6MWT category, and
baseline measurement (3MSCT and uKS only).
e P-value determined by t-test and the repeated measures ANCOVA model.
137C.J. Hendriksz et al. / Molecular Genetics and Metabolism 119 (2016) 131–143distances than those who did not; both groups maintained their initial
improvements throughout the study (Appendix Fig. B2). Age was also
evaluated and no clear impact on 6MWT results was detected
(Appendix Fig. B3).
3.3. Secondary efﬁcacy measures
3.3.1. 3MSCT
Mean (SE) changes from pre-treatment baseline in the 3MSCT for
the QW-QW cohort were 4.6 (1.1), 5.9 (1.1), 5.0 (1.4), and 5.5
(1.9) stairs/min and 3.9 (1.2), 5.5 (1.3), 5.7 (1.5), and 6.7 (2.0) stairs/
min at 24, 36, 72, and 120 weeks in the ITT (Fig. 4A) and MPP
(Fig. 4B) populations, respectively. Mean (SE) changes in the 3MSCT
for all cohorts pooled were 4.8 (1.2), 5.0 (0.8), 5.2 (1.0), and 4.3
(1.2) stairs/min and 4.4 (0.8), 5.5 (0.9), 7.0 (1.1), 6.8 (1.3) stairs/min
at 24, 36, 72, and 120weeks in the ITT andMPP populations, respective-
ly (Fig. 4C). Assuming similar timing of approximately 1 and 2 years
follow-up in MorCAP and MOR-004/005, model-based ANCOVA analy-
sis demonstrates a signiﬁcant difference in change from baseline for
treated versus untreated patients, for both ITT and MPP populations in
the QW-QW cohort and all cohorts pooled (Fig. 5, Table 2).
3.3.2. Normalized uKS
Unlike endurance measures, normalized uKS is not inﬂuenced by
factors such as joint abnormalities, neurological problems, patientmoti-
vation, or orthopedic surgeries. Response to treatment is, therefore,
more robust, allowing for interpretation of the uKS results by individual
treatment cohort. The rapid decline in normalized uKS seen inMOR-004
in patients on elosulfase alfa treatment [8]was followedby a continuous
gradual decline inMOR-005 (Fig. 6). In patients who switched frompla-
cebo to elosulfase alfa at the beginning of MOR-005, a rapid initialdecline in uKS was observed. Patients receiving elosulfase every other
week during part 1 of the study experienced slower declines in uKS
than those receiving weekly treatment. Cohorts receiving every other
week treatment showed a further gradual decline in uKS when
transitioned to weekly doses, further supporting the ﬁnding from the
pivotal study [8] that weekly treatment is necessary for optimal effect.
Reductions in uKS were seen regardless of age cohort (data not
shown). By Week 120, when all patients were receiving weekly
treatment, the mean percent change from baseline was similar for
all cohorts. Mean (SE) change in normalized uKS was −59.4
(1.8)% in the pooled ITT population and −62.3 (1.8)% in the pooled
MPP population. These changes resulted in mean 120 week uKS
levels of 10.2 and 8.5 μg/mg creatinine in the pooled ITT and MPP
populations, respectively.
Assuming similar timingof approximately 1 and 2 years follow-up in
MorCAP and MOR-004/005, model-based ANCOVA analysis demon-
strates a highly signiﬁcant (P ˂ 0.0001) difference in change from base-
line for treated versus untreated patients, for both the QW-QW cohort
and the pooled study population (ITT and MPP) (Table 2).
3.4. Safety
Table 3 summarizes AEs and serious AEs (SAEs) reported for all
patients (ITT population) during MOR-005 by treatment cohort. No
new or unexpected safety signalswere identiﬁed since the original pub-
lication. The safety proﬁle was consistent with that observed in MOR-
004 and the post-marketing setting to date.
The most commonly reported AEs overall were mild to moderate
IARs such as vomiting, pyrexia, and headache, which were generally
manageable with symptomatic treatment and/or infusion rate modiﬁ-
cation. While all patients reported at least one AE during the study,
Fig. 4.Mean (SE) change frombaseline in 3MSCT results over 120weeks for treatment cohorts individually (A, B) and pooled (C) for ITT andMPP populations. The number of patientswith
data available are shown below each time point.
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Fig. 5. LS mean 3MSCT changes from baseline (stairs/min) over approximately 2 years in MOR-004/005 QW-QW and pooled ITT and MPP populations and the corresponding untreated
subpopulations from the MorCAP natural history study, MorCAP 1 and 2, respectively. The number of patients with data available are shown below each time point. LS mean changes are
based on repeated measures ANCOVAmodel including treatment, time point, treatment and time point interaction, age group, baseline 6MWT category, and baseline measurement.
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infusions administered, 81 (0.5%) were interrupted or discontinued be-
cause of an AE requiring medical intervention.
Most SAEs occurringduringMOR-005were related to planned surgi-
cal procedures, which were allowed in MOR-005, but not in MOR-004.Fig. 6. Percentagemean (SE) change from baseline in normalized uKS over 120weeks for individ
shown below each time point.Therewere two study-drug related SAEswhich occurred in separate pa-
tients, anaphylaxis (grade 4) and hematuria (grade 2). One death unre-
lated to elosulfase alfa occurred due to postoperative pulmonary
complications secondary to spinal cord compression, laminectomy,
and spinal fusion.ual treatment cohorts from ITT population. The number of patientswith data available are
Table 3
Overall summary of adverse events during MOR-005 (ITT population).
PBO-QOW (N= 29) PBO-QW (N= 29) QOW-QOW (N= 59) QW-QW (N= 56)
Any AE, N (%) 29 (100.0%) 29 (100.0%) 59 (100.0%) 56 (100.0%)
Number of AEs per patient, N
Mean 39.9 24.9 30.8 35.9
Median 30.0 18.0 24.0 26.5
Any study drug-related AE, N (%) 23 (79.3%) 20 (69.0%) 40 (67.8%) 43 (76.8%)
Any SAE, N (%) 16 (55.2%) 14 (48.3%) 24 (40.7%) 23 (41.1%)
Number of SAEs per subject, N
Mean 0.8 0.7 0.7 0.7
Median 1.0 0.0 0.0 0.0
Any study drug-related SAE, N (%) 2 (6.9%) 0 (0%) 0 (0%) 0 (0%)
Any AE leading to permanent study drug discontinuation, N (%) 0 (0%) 0 (0%) 3 (5.1%) 1 (1.8%)
Death, N (%) 0 (0%) 0 (0%) 1 (1.7%) 0 (0%)
AE: adverse event; SAE: serious adverse event.
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bodies, and nearly all developed NAb (antibodies capable of interfering
with CI-M6PR binding in vitro). At Week 120, 100% of patients were
positive for total antibody (TAb) directed against elosulfase alfa
(Fig. 7a), and a majority were positive for NAb. No association was de-
tected between higher TAb titer or NAb positivity and reduced efﬁcacy
measurements (6MWT, 3MSCT, and uKS) (Fig. 7b-d) or the incidence
or severity of hypersensitivity AEs. Drug-speciﬁc IgE was detected in
17/176 (9.7%) subjects in the ITTpopulation byWeek 120, and positivity
was not consistently associated with the occurrence of anaphylaxis,
other hypersensitivity AEs, and/or treatment withdrawal.
4. Discussion
Initial improvements in endurance and reductions in uKS reported
in the elosulfase alfa pivotal study [8] were sustained in this extension
study over a total of 120 weeks. For patients treated with elosulfase
alfa at 2.0 mg/kg/week throughout the study, mean 6MWT improve-
ments from baseline were 32.0 and 39.9 m for the ITT and MPP popula-
tions, respectively, as compared to the 22.5m improvement reported in
the pivotal study [8]. Although the minimal clinically important differ-
ence (MCID) in the 6MWThas not yet been identiﬁed forMorquio A pa-
tients, it was noted in the pivotal study publication that the level of
improvement seen with elosulfase alfa falls within the spectrum of
6MWT MCIDs identiﬁed for other disorders [8].
Sustained improvements of 5.5 and 6.7 stairs/min in the 3MSCT at
120 weeks for the weekly treatment cohort (ITT and MPP populations,
respectively) corroborated the 6MWT ﬁndings, as did sustained reduc-
tions in uKS. Interestingly, uKS levels continued to decline gradually,
even after 72 weeks, suggesting possible continued depletion of stored
glycosaminoglycan with long-term treatment. Alternatively, the gradu-
al decline seen may be a result of the decline in uKS levels that occurs
with age, or a combination of both factors.
Interpretation of results from this extension study was complicated
by several factors, including the staggered transition to the weekly dos-
ing regimen, occurrence of orthopedic surgeries among the patients,
and absence of a placebo group. While transitioning all patients to QW
dosing of elosulfase alfa at the time the optimal treatment regimen
was identiﬁed contributed to the complexity of the study, the decision
to do so was deemed to be in the best interest of the patients.
Due to the severe skeletal involvement of Morquio A patients and
the importance of surgical management of symptoms, orthopedic sur-
geries could not be delayed for the duration of the extension study. En-
durance test results may have been compromised by the orthopedic
surgeries and subsequent recovery periods for 38 of the 173 patients.
Alternatively, potential improvements resulting from surgical interven-
tions could also bias the results. Therefore, these patientswere excluded
from the MPP population. Excluding patients undergoing orthopedic
surgery during the study had the potential to bias the results if those pa-
tients were more severely affected. However, ITT and MPP populationshad similar baseline 3MSCT and uKS means and the MPP population
had a lower 6MWT mean than the ITT population (201.6 versus
209.5 m). Therefore, in this study, the need for orthopedic surgery
does not appear to have been indicative of severity of endurance limita-
tion or uKS levels.
A placebo group was not included as continuing invasive weekly in-
fusions in the absence of treatment for the duration of this long-term
extension study was considered unethical. In the absence of a placebo
group, a direct evaluation of treatment efﬁcacy could not be made.
However, data from untreated patients, available from theMorCAP nat-
ural history study,were used to place the results of this study in the con-
text of a progressive disease. Themain limitations to these comparisons
were the decreasing number of observations available for analysis at
later time points of the MorCAP study and the potential for differences
between the MOR-004/005 and MorCAP populations and study execu-
tions. The fact that some (exact number could not be determined from
available data) MorCAP patients subsequently enrolled in MOR-004/
005 and are, therefore, providing data to both populations, should also
be noted.
To establish the untreated population to be used for comparison,
MorCAP patients were evaluated by the inclusion and exclusion
criteria for MOR-004/005 to the extent possible. The MPP population
excluded patients who were non-compliant as determined by
missed infusions equaling or exceeding 20%, however, as MorCAP
patients were untreated, these criteria could not be applied. Ulti-
mately, comparison of MorCAP 2 and MPP population baseline data
reveal similar endurance results, although uKS is slightly higher in
the MorCAP 2 population.
When compared to the corresponding MorCAP subpopulations,
MOR-005 ITT andMPP populations' 6MWT and uKS results demonstrat-
ed sustained treatment effects at both 1 and 2 years (P b 0.05). These ef-
fects are greater if only patients receiving the optimal dose for
120 weeks are considered. For 3MSCT results, which did not reach sig-
niﬁcance during MOR-004, statistical signiﬁcance was achieved over
the long-term MOR-005 study, in both the ITT and MPP populations,
at 1 and 2 years versus the MorCAP subpopulation (P b 0.05). The
more gradual course of 3MSCT improvement, as compared to 6MWT
improvement, is noteworthy and may indicate that the 3MSCT is less
sensitive to shorter term treatment effects than the 6MWT in Morquio
A patients. This may be due to the increased challenge stair-climbing
poses for Morquio A patients in comparison to walking in the 6MWT,
due to extremely short stature and disease involvement of the ankles,
knees, and hips, as well as the upper extremities which aid in stair
climbing via the hand rail.
A signiﬁcant correlation has recently been reported between clinical
6MWT and 3MSCT outcomes and patient-reported quality of life out-
comes [12]. Results from a Morquio A patient-reported outcomes sur-
vey indicated that quality of life is mainly dependent upon the
patient's ability to remain independently mobile and that even slight
improvements in mobility dramatically improve quality of life [5]. The
Fig. 7. TAb titer of patients in the ITT population (A) over time in those receiving treatment duringMOR-004 andMOR-005 (treated) and those receiving placebo duringMOR-004 and treatment duringMOR-005 (placebo/treated); (B–D) atWeek 120
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maywell enable patients to decrease their dependence on awheelchair,
increasing theirmobility and independence, lessening caregiver burden,
and improving their quality of life.
5. Conclusions
In the context of a chronic progressive disease, elosulfase alfa ERT led
to improvements in endurance which were sustained over 120 weeks.
Improvement and subsequent stabilization seen in 6MWT and 3MSCT
results signiﬁcantly differed from the gradual decline seen in corre-
sponding subpopulations of untreated patients from the MorCAP natu-
ral history study. Initial endurance improvements were maintained
regardless of the endurance capacity of patients at baseline, use of a
walking aid, and age. Long-term treatment resulted in sustained reduc-
tion of uKS levels. The development of anti-drug antibodies had no ap-
parent impact on long-term endurance outcomes or uKS levels and no
impact on long-term drug safety/tolerability. No new or unexpected
safety signals were identiﬁed. Ultimately, the beneﬁts of elosulfase alfa
ERT are enduring and appear to substantially alter the expected course
of disease for Morquio A patients.
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